Want to see NCEL full AI Analyst Report?
NCEL Stock Chart & Stats
$2.66
--
Market closed
$2.66
--
Day’s Range― - ―
52-Week Range$1.83 - $28.03
Previous CloseN/A
VolumeN/A
Average Volume (3M)320.89K
Market Cap
$22.61M
Enterprise Value-$1.65M
Total Cash (Recent Filing)$2.20M
Total Debt (Recent Filing)$355.00K
Price to Earnings (P/E)―
Beta0.88
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,345,184
10 Day Avg. Volume34,320
30 Day Avg. Volume320,894
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-2.63
Enterprise Value/Market Cap-0.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit833.27
Enterprise Value/Ebitda0.51
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Alignment: FDA Pre-INDA constructive Type B Pre-IND meeting with the FDA materially lowers regulatory uncertainty for NCEL-101. Favorable CMC and preclinical feedback clears key IND-enabling paths, improving the program’s ability to reach first-in-human trials and de-risk timelines that underpin long-term value creation.
Strategic Collaboration With EledonPairing an off-the-shelf islet cell therapy with an investigational immunomodulator creates a differentiated therapeutic approach. Leveraging Eledon’s transplant data may raise success probability, strengthen clinical rationale, and enhance partner-driven resources and commercialization prospects over the medium term.
Peer-reviewed External ValidationA peer-reviewed publication validating AstroRx bolsters scientific credibility of NewcelX’s stem-cell platform. Independent academic validation supports broader indication potential, helps attract collaborators, and reduces translational risk across pipeline assets over a 2–6 month horizon and beyond.
Bears Say
No Revenue; Sustained LossesThe company reports no product revenue and persistent net losses, meaning it cannot self-fund development from operations. This structural absence of operating income imposes ongoing reliance on external capital and increases execution risk if clinical progress slows or costs rise.
Consistent Negative Free Cash FlowNegative operating and free cash flow each year—where FCF closely tracks net loss—shows cash burn is real and recurring. The deterioration in 2025 highlights limited internal runway and a structural funding gap that can constrain trial timelines or force dilutive financings.
Thin Cash Runway; Financing DependenceLow year-end cash and reliance on a small private placement plus an equity line indicate dependence on capital markets. While debt is low, recurring funding needs raise dilution risk and governance pressures if milestones slip, making long-term program continuity contingent on future raises.
NewcelX News
NCEL FAQ
What was NewcelX’s price range in the past 12 months?
NewcelX lowest stock price was $1.83 and its highest was $28.03 in the past 12 months.
What is NewcelX’s market cap?
NewcelX’s market cap is $22.61M.
When is NewcelX’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were NewcelX’s earnings last quarter?
Currently, no data Available
Is NewcelX overvalued?
According to Wall Street analysts NewcelX’s price is currently Overvalued.
Does NewcelX pay dividends?
NewcelX does not currently pay dividends.
What is NewcelX’s EPS estimate?
NewcelX’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NewcelX have?
NewcelX has 5,345,184 shares outstanding.
What happened to NewcelX’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NewcelX?
Currently, no hedge funds are holding shares in NCEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NewcelX
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
Ownership Overview
Options Prices
Currently, No data available
---